Equities

Taiko Pharmaceutical Co Ltd

4574:TYO

Taiko Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)373.00
  • Today's Change7.00 / 1.91%
  • Shares traded88.60k
  • 1 Year change+15.84%
  • Beta0.5931
Data delayed at least 20 minutes, as of Nov 13 2024 04:03 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments5,4843,5056,098
Total Receivables, Net1,9851,7984,056
Total Inventory1,3731,9523,205
Prepaid expenses------
Other current assets, total267301424
Total current assets9,1097,55613,783
Property, plant & equipment, net3,5816,3977,113
Goodwill, net------
Intangibles, net1.00222299
Long term investments2365331,011
Note receivable - long term------
Other long term assets292336329
Total assets13,22015,04622,535
LIABILITIES
Accounts payable375274309
Accrued expenses7523149
Notes payable/short-term debt000
Current portion long-term debt/capital leases1,2331,068959
Other current liabilities, total1,3631,4282,903
Total current liabilities3,0462,7934,320
Total long term debt2,0212,7413,814
Total debt3,2543,8094,773
Deferred income tax188125104
Minority interest------
Other liabilities, total1,2261,3431,490
Total liabilities6,4817,0029,728
SHAREHOLDERS EQUITY
Common stock2,2671,2011,201
Additional paid-in capital2,6891,6421,648
Retained earnings (accumulated deficit)1,6285,23910,134
Treasury stock - common(300)(348)(388)
Unrealized gain (loss)91----
Other equity, total364310212
Total equity6,7398,04412,807
Total liabilities & shareholders' equity13,22015,04622,535
Total common shares outstanding504444
Treasury shares - common primary issue0.490.560.56
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.